The conversation centred on the company’s latest developments and strategic direction in cancer therapies, with a particular ...

What trends did delegates notice, in terms of new modalities, technologies, and approaches? Precision, personalisation, and ...

Summit Pharma has revealed that a second pivotal trial of its Akeso-partnered PD-1xVEGF bispecific ivonescimab has failed to ...

The deal with Evopoint boosts Astellas' claudin pipeline as other CLDN18.2 candidates come through the industry pipeline from ...

Roche has revealed new results from a phase 2 trial of its oral BTK inhibitor fenebrutinib in relapsing multiple sclerosis ...

Philippe Masset has been appointed to the Board of Directors at Vect-Horus, a French biotech developing vectors for targeting ...

Op den Kelder grew up in the Netherlands and received his Bachelor’s degree in International Management from Fontys ...

Stealth refrained from criticising the FDA's decision on its application, which comes after the agency missed its own ...

Angelini is paying $50 million upfront for ex-North American rights to radiprodil, with another $520 million in the offing in ...

A year ago, MSD and Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) was rejected by ...

Axtria’s flagship event is almost here! Axtria Ignite 2025 is taking place 4th to 5th June at the Princeton Marriott at ...

The PMCPA also agreed with the complainant that Pfizer had not taken all possible steps to avoid similar breaches in its ...